WO2020085826A1 - 육두구 추출물 또는 메이스리그난을 유효성분으로 함유하는 환경오염인자로부터 유도되는 피부자극 완화 및 피부보호용 조성물 - Google Patents
육두구 추출물 또는 메이스리그난을 유효성분으로 함유하는 환경오염인자로부터 유도되는 피부자극 완화 및 피부보호용 조성물 Download PDFInfo
- Publication number
- WO2020085826A1 WO2020085826A1 PCT/KR2019/014101 KR2019014101W WO2020085826A1 WO 2020085826 A1 WO2020085826 A1 WO 2020085826A1 KR 2019014101 W KR2019014101 W KR 2019014101W WO 2020085826 A1 WO2020085826 A1 WO 2020085826A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- skin
- nutmeg extract
- nutmeg
- formula
- derived
- Prior art date
Links
- 239000001702 nutmeg Substances 0.000 title claims abstract description 156
- 229940098295 nutmeg extract Drugs 0.000 title claims abstract description 119
- 239000000203 mixture Substances 0.000 title claims abstract description 92
- QDDILOVMGWUNGD-UONOGXRCSA-N 4-[(2S,3R)-4-(1,3-benzodioxol-5-yl)-2,3-dimethylbutyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC(C[C@H](C)[C@H](C)CC=2C=C3OCOC3=CC=2)=C1 QDDILOVMGWUNGD-UONOGXRCSA-N 0.000 title claims abstract description 91
- QDDILOVMGWUNGD-UHFFFAOYSA-N Macelignan Natural products C1=C(O)C(OC)=CC(CC(C)C(C)CC=2C=C3OCOC3=CC=2)=C1 QDDILOVMGWUNGD-UHFFFAOYSA-N 0.000 title claims abstract description 91
- 206010040880 Skin irritation Diseases 0.000 title claims abstract description 84
- 231100000475 skin irritation Toxicity 0.000 title claims abstract description 84
- 230000036556 skin irritation Effects 0.000 title claims abstract description 83
- 239000004480 active ingredient Substances 0.000 title claims abstract description 47
- 238000003912 environmental pollution Methods 0.000 title claims abstract description 37
- 230000004224 protection Effects 0.000 title claims abstract description 33
- 239000002537 cosmetic Substances 0.000 claims abstract description 22
- 235000013305 food Nutrition 0.000 claims abstract description 21
- 235000009421 Myristica fragrans Nutrition 0.000 claims description 41
- 241000498779 Myristica Species 0.000 claims description 33
- 239000003344 environmental pollutant Substances 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 27
- 238000011109 contamination Methods 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- 238000002360 preparation method Methods 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 239000000126 substance Substances 0.000 claims description 17
- 230000007613 environmental effect Effects 0.000 claims description 13
- 239000000356 contaminant Substances 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 9
- 201000004624 Dermatitis Diseases 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 3
- 206010000496 acne Diseases 0.000 claims description 3
- 208000010668 atopic eczema Diseases 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 206010003645 Atopy Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 29
- 239000000428 dust Substances 0.000 abstract description 16
- 230000001404 mediated effect Effects 0.000 abstract description 16
- 108010074918 Cytochrome P-450 CYP1A1 Proteins 0.000 abstract description 14
- 230000002829 reductive effect Effects 0.000 abstract description 4
- 239000005445 natural material Substances 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 90
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 39
- 239000013618 particulate matter Substances 0.000 description 38
- 229930013686 lignan Natural products 0.000 description 29
- 235000009408 lignans Nutrition 0.000 description 29
- 150000005692 lignans Chemical class 0.000 description 29
- 230000002401 inhibitory effect Effects 0.000 description 21
- 238000000605 extraction Methods 0.000 description 19
- 239000000284 extract Substances 0.000 description 17
- 239000004615 ingredient Substances 0.000 description 17
- 108060001084 Luciferase Proteins 0.000 description 16
- 239000005089 Luciferase Substances 0.000 description 16
- FMMWHPNWAFZXNH-UHFFFAOYSA-N ERM-AC051 Natural products C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 15
- 150000003839 salts Chemical class 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- 102100031476 Cytochrome P450 1A1 Human genes 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 238000002156 mixing Methods 0.000 description 13
- 238000007796 conventional method Methods 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 108020004999 messenger RNA Proteins 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 244000270834 Myristica fragrans Species 0.000 description 11
- 239000006071 cream Substances 0.000 description 11
- 239000003755 preservative agent Substances 0.000 description 11
- 102000003984 Aryl Hydrocarbon Receptors Human genes 0.000 description 9
- 108090000448 Aryl Hydrocarbon Receptors Proteins 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000000469 ethanolic extract Substances 0.000 description 9
- 239000003205 fragrance Substances 0.000 description 9
- 239000000049 pigment Substances 0.000 description 9
- 230000037380 skin damage Effects 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 210000002615 epidermis Anatomy 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 235000013402 health food Nutrition 0.000 description 7
- 239000006210 lotion Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 229940002612 prodrug Drugs 0.000 description 7
- 239000000651 prodrug Substances 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 description 6
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 description 6
- 102100027417 Cytochrome P450 1B1 Human genes 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 101000725164 Homo sapiens Cytochrome P450 1B1 Proteins 0.000 description 6
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 230000009759 skin aging Effects 0.000 description 5
- 239000000344 soap Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 239000002562 thickening agent Substances 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 229920001214 Polysorbate 60 Polymers 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 229910001385 heavy metal Inorganic materials 0.000 description 4
- 239000002035 hexane extract Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 239000012188 paraffin wax Substances 0.000 description 4
- 230000000704 physical effect Effects 0.000 description 4
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 4
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 4
- 229940113124 polysorbate 60 Drugs 0.000 description 4
- 239000004576 sand Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000000809 air pollutant Substances 0.000 description 3
- 231100001243 air pollutant Toxicity 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 239000002024 ethyl acetate extract Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 238000000194 supercritical-fluid extraction Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 2
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- 241001081833 Myristicaceae Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 2
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 2
- 229920002230 Pectic acid Polymers 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 235000015895 biscuits Nutrition 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 229940112822 chewing gum Drugs 0.000 description 2
- 235000015218 chewing gum Nutrition 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000005100 correlation spectroscopy Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 239000000417 fungicide Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000000401 methanolic extract Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- GSGDTSDELPUTKU-UHFFFAOYSA-N nonoxybenzene Chemical compound CCCCCCCCCOC1=CC=CC=C1 GSGDTSDELPUTKU-UHFFFAOYSA-N 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920005547 polycyclic aromatic hydrocarbon Polymers 0.000 description 2
- 125000005575 polycyclic aromatic hydrocarbon group Polymers 0.000 description 2
- 239000002861 polymer material Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000037307 sensitive skin Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- HBZBAMXERPYTFS-SECBINFHSA-N (4S)-2-(6,7-dihydro-5H-pyrrolo[3,2-f][1,3]benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 HBZBAMXERPYTFS-SECBINFHSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- TXVHTIQJNYSSKO-UHFFFAOYSA-N BeP Natural products C1=CC=C2C3=CC=CC=C3C3=CC=CC4=CC=C1C2=C34 TXVHTIQJNYSSKO-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000173371 Garcinia indica Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000006417 Leucas aspera Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000023984 PPAR alpha Human genes 0.000 description 1
- 244000220503 Persea thunbergii Species 0.000 description 1
- 235000004267 Persea thunbergii Nutrition 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 101150057615 Syn gene Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- BIOSEDSLNBFVPI-UHFFFAOYSA-N [Mg].C=Cc1ccccc1 Chemical compound [Mg].C=Cc1ccccc1 BIOSEDSLNBFVPI-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- HTRXGEPDTFSKLI-UHFFFAOYSA-N butanoic acid;ethyl acetate Chemical compound CCCC(O)=O.CCOC(C)=O HTRXGEPDTFSKLI-UHFFFAOYSA-N 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000013574 canned fruits Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 229940126523 co-drug Drugs 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000000498 cooling water Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 101150055214 cyp1a1 gene Proteins 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229910000393 dicalcium diphosphate Inorganic materials 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 229940125542 dual agonist Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 239000002038 ethyl acetate fraction Substances 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000002803 fossil fuel Substances 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 235000013324 preserved food Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- CEAYCPAHSNTNGO-UHFFFAOYSA-M sodium;ethane-1,2-diamine;acetate Chemical compound [Na+].CC([O-])=O.NCCN CEAYCPAHSNTNGO-UHFFFAOYSA-M 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000006211 transdermal dosage form Substances 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940033203 vitamin b6 0.5 mg Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
- 230000002034 xenobiotic effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Definitions
- the present invention relates to a composition for alleviating skin irritation and protecting skin derived from environmental pollutants containing nutmeg extract or mace lignan as an active ingredient, and more specifically, mace lignan represented by Formula 1 of the present invention or nutmeg containing the same It relates to a composition for skin irritation relief and skin protection derived from environmental pollution factors containing the extract as an active ingredient.
- the skin protects the organs in the body from stimulation of the external environment and plays an important role in maintaining bio homeostasis such as body temperature control.
- exposure to excessive ultraviolet rays or pollutants causes skin irritation and eventually leads to skin aging.
- fine dust and yellow sand mixed with harmful substances such as heavy metals are known to be major causes of skin aging and skin damage (J. Prev. Med. Public Health, 39: 205-212, 2006 ).
- PM 10 Particulate matter (PM) 10 is collectively referred to a particle size of 10 ⁇ m or less fine dust and fine particles less than 2.5 ⁇ m in seconds is divided into a PM 2.5.
- Fine dust is mainly generated when burning fossil fuels, and fine dust from China, which has a 70% dependency on coal, accounts for a large portion.
- yellow sand is a phenomenon in which small sand or loess is floating in the inland deserts of China and Mongolia, and is transported away by upper winds and falls near the ground. About 25 to 33% of diseases in industrialized countries are caused by environmental hazards.
- Myristica fragrans belongs to the Myristicaceae family, and the seeds of Myristica fragrans are called nutmeg. So far, activities related to nutmeg have been reported such as detoxification, anti-diabetes, and anti-inflammatory effects.
- the representative ingredient contained in the nutmeg extract, macelignan is a PPAR ⁇ / ⁇ dual agonist, and has been reported to have anti-diabetes, liver protection, neuroprotection, antibacterial, and antioxidant activities.
- the present inventors searched for substances having a skin irritation relief and skin protection function derived from environmental pollutants derived from natural products, and found that nutmeg extract or mace lignan has a skin irritation relief and skin protection function derived from environmental pollution factors.
- the present invention was completed by clarification.
- an object of the present invention is to provide a pharmaceutical composition for alleviating skin irritation and protecting skin derived from environmental pollutants containing nutmeg extract or mayslignan as an active ingredient.
- an object of the present invention is to provide a pharmaceutical composition for alleviating skin irritation and protecting skin derived from environmental pollution factors consisting of nutmeg extract or mays lignan as an active ingredient.
- an object of the present invention is to provide a pharmaceutical composition for alleviating skin irritation and skin protection derived from environmental pollution factors consisting essentially of nutmeg extract or mays lignan as an active ingredient.
- Another object of the present invention is to provide a food composition for alleviating skin irritation and skin protection derived from environmental contaminants containing nutmeg extract or mace lignan as an active ingredient.
- Another object of the present invention is to provide a food composition for skin irritation relief and skin protection derived from environmental pollutants consisting of nutmeg extract or macy lignan as an active ingredient.
- Another object of the present invention is to provide a food composition for alleviating skin irritation and skin protection derived from environmental pollution factors consisting essentially of nutmeg extract or mays lignan as an active ingredient.
- Another object of the present invention is to provide a cosmetic composition for skin irritation relief and skin protection derived from environmental pollutants containing nutmeg extract or macy lignan as an active ingredient.
- Another object of the present invention is to provide a cosmetic composition for alleviating skin irritation and protecting skin derived from environmental pollution factors consisting of nutmeg extract or mays lignan as an active ingredient.
- Another object of the present invention is to provide a cosmetic composition for skin irritation relief and skin protection derived from environmental pollutants consisting essentially of nutmeg extract or mace lignan as an active ingredient.
- Another object of the present invention is to provide a composition for preventing skin contamination derived from environmental contaminants containing nutmeg extract or mace lignan as an active ingredient.
- Another object of the present invention is to provide a composition for preventing skin contamination derived from environmental pollution factors consisting of nutmeg extract or mays lignan as an active ingredient.
- Another object of the present invention is to provide a composition for preventing skin contamination derived from environmental pollutants consisting essentially of nutmeg extract or mace lignan as an active ingredient.
- Another object of the present invention is to provide a use of mace lignan or a nutmeg extract containing the same for preparing a preparation for skin irritation relief and skin protection derived from environmental pollution factors.
- Another object of the present invention is a method for alleviating skin irritation and protecting skin induced from environmental pollutants, characterized by administering an effective amount of a composition containing mace lignan or nutmeg extract containing it as an active ingredient to an individual in need thereof. Is to provide.
- Another object of the present invention is to provide a use of mace lignan or nutmeg extract containing the same for preparing a formulation for preventing skin contamination derived from environmental pollution factors.
- Another object of the present invention is to provide a method for preventing skin contamination derived from environmental pollution factors, characterized by administering an effective amount of a composition containing mace lignan or nutmeg extract containing it as an active ingredient to an individual in need thereof. .
- the present invention provides a pharmaceutical composition for alleviating skin irritation and protecting skin derived from environmental contaminants containing nutmeg extract or mays lignan as an active ingredient.
- the present invention provides a pharmaceutical composition for alleviating skin irritation and protecting skin derived from environmental pollutants consisting of nutmeg extract or mace lignan as an active ingredient.
- the present invention provides a pharmaceutical composition for alleviating skin irritation and protecting skin derived from environmental pollutants consisting essentially of nutmeg extract or macylignan as an active ingredient.
- the present invention provides a food composition for alleviating skin irritation and protecting skin derived from environmental contaminants containing nutmeg extract or mace lignan.
- the present invention provides a food composition for skin irritation relief and skin protection derived from environmental pollutants consisting of nutmeg extract or mace lignan.
- the present invention provides a food composition for alleviating skin irritation and protecting skin derived from environmental pollution factors consisting essentially of nutmeg extract or mace lignan.
- the present invention provides a cosmetic composition for alleviating skin irritation and protecting skin derived from environmental contaminants containing nutmeg extract or mace lignan.
- the present invention provides a cosmetic composition for skin irritation relief and skin protection derived from environmental pollutants consisting of nutmeg extract or mace lignan.
- the present invention provides a cosmetic composition for alleviating skin irritation and protecting skin derived from environmental pollution factors consisting essentially of nutmeg extract or mace lignan.
- the present invention provides a composition for preventing skin contamination derived from environmental pollution factors containing nutmeg extract or mace lignan as an active ingredient.
- the present invention provides a composition for preventing skin contamination derived from environmental pollutants consisting of nutmeg extract or mace lignan as an active ingredient.
- the present invention provides a composition for preventing skin contamination derived from environmental pollutants consisting essentially of nutmeg extract or mace lignan as an active ingredient.
- the present invention provides the use of mace lignan or a nutmeg extract containing the same to prepare a formulation for skin irritation relief and skin protection derived from environmental pollution factors.
- the present invention derives from an environmental contaminant characterized by administering an effective amount of a composition containing mace lignan or nutmeg extract containing it as an active ingredient to an individual in need thereof.
- a composition containing mace lignan or nutmeg extract containing it as an active ingredient to an individual in need thereof.
- the present invention provides the use of mace lignan or nutmeg extract containing the same for preparing a formulation for preventing skin contamination derived from environmental pollution factors.
- the present invention derives from an environmental contaminant characterized by administering an effective amount of a composition containing mace lignan or nutmeg extract containing it as an active ingredient to an individual in need thereof. Provide a method for preventing contamination.
- the present invention provides a pharmaceutical composition for alleviating skin irritation and protecting skin derived from environmental contaminants containing nutmeg extract or mace lignan as an active ingredient.
- the nutmeg extract is a Myristica plant of the Myristicaceae , and the seed of the myristica fragrant may be an extract target.
- the nutmeg extract may be extracted using water, an organic solvent having 1 to 6 carbon atoms, or a mixture thereof as a solvent.
- the organic solvent is C1 to C6 lower alcohol (alcohol), acetone (acetone), ether (ether), benzene (benzene), chloroform (chloroform), ethyl acetate (ethyl acetate), methylene chloride (methylene chloride),
- One or more selected from the group consisting of hexane, cyclohexane and petroleum ether is preferred, but is not limited thereto.
- the lower alcohol used in the extraction of the nutmeg is also more preferably ethanol or methanol, most preferably ethanol.
- the extraction temperature is preferably 20 ° C to 100 ° C, and more preferably 60 ° C to 100 ° C, but is not limited thereto.
- the extraction time is preferably 1 hour to 10 hours, more preferably 2 hours to 5 hours, but is not limited thereto.
- Cold extraction, ultrasonic extraction, or reflux cooling extraction may be used as the extraction method, and it is preferable to use a reflux cooling extraction method, but is not limited thereto.
- the number of extractions is preferably 1 to 5 times, and it is more preferable to repeatedly extract 2 to 3 times, but is not limited thereto.
- the nutmeg extract may be performed by an ultra-high pressure, subcritical fluid or supercritical fluid extraction method.
- Nutmeg used for extraction can be used after washing after harvesting or dried.
- a drying method a dry method, a dry method, a hot air drying method, and a natural drying method may be used.
- nutmeg or its dry matter may be crushed and used.
- the macelignan preferably has the structure of Formula 1 below.
- Macelignan (macelignan) of the present invention has a structure of formula 1, can be purified from nature, commercially available for use, or prepared by chemical synthesis methods known in the art.
- the machlignan of the present invention may be purified from nature. More preferably, it can be isolated and purified from Myristica fragrans , and most preferably, it can be isolated and purified from nutmeg or aril of Myristica fragrans .
- Another nutmeg, Myristica Myristica argentea Warb) (Nat. Prod. Lett., 16: 1-7, 2002), and Machilus thunbergii ) (Bio. Pharm. Bull., 27: 1305-1307, 2004), Leucas aspera , etc. (Chem. Pharm. Bull., 51: 595-598, 2003) .
- the may lignan of the present invention may be separated and purified from a nutmeg by a solvent extraction method known in the art and a separation method using chromatography.
- the composition according to the present invention can be used for alleviating skin irritation and protecting skin and preventing skin contamination derived from environmental pollutants by reducing the expression level of a gene mediated by XRE.
- composition of the present invention has a skin irritation alleviation and skin protection effect, and such skin irritation is a skin disease caused by deterioration of skin function due to environmental pollution factors, promotion of skin aging, etc., and is preferably a disease reported in the art. And protection.
- Skin irritation of the present invention is more preferably any one or more selected from the group consisting of dermatitis, atopy, psoriasis, acne, skin cancer, eczema, It is not limited to this.
- the skin irritation relief of the present invention may be "anti-pollution of the skin".
- Prevention of skin contamination improves skin condition by protecting the skin from natural factors (endogenous aging) or environmental pollutants (poly aromatic hydrocarbons, particulate matter, tobacco smoke, yellow sand or heavy metals, etc.) It means to induce, preferably to protect the skin from environmental pollution factors.
- the term “mayslignan represented by Formula 1 or nutmeg extract containing the same” is considered to include their pharmaceutically acceptable salts or prodrugs thereof.
- 'prodrug' in the present invention is a biotransformation in order to secrete or convert a prodrug into an active drug (eg, enzymatically, physiologically, mechanically, electromagnetically) in a targeted physiological system.
- an active drug eg, enzymatically, physiologically, mechanically, electromagnetically
- a pharmaceutically inert derivative of the source 'drug' molecule eg, primary or enzymatic
- Prodrugs are designed to overcome problems associated with stability, toxicity, lack of specificity or limited bioavailability.
- Typical prodrugs include the active drug molecule itself and a chemical blocking group (e.g., a group that reversely inhibits the drug's activity).
- Some preferred drugs are variants or derivatives of components with separable groups depending on metabolic conditions.
- Typical drugs are pharmacologically activated both in vitro and in vitro when solvolysis under physiological conditions, enzymatic degradation, or other biochemical modifications (e.g. phosphorylation, hydrogenation, dehydrogenation, glycosylation reactions) are performed.
- Prodrugs often offer advantages such as solubility, histocompatibility, or sustained release in the mammalian body.
- Common prodrugs include acid derivatives such as esters obtained by reacting a suitable alcohol (e.g., lower alkanols) with source acids, acylated base derivatives formed by reaction of amides or basic groups with amines and source acid components ( For example, lower alkylamide).
- the nutmeg extract or mayslignan of the present invention may be included in the composition in the form of a pharmaceutically acceptable salt.
- “Pharmaceutically acceptable salt” refers to a physiologically acceptable salt that does not cause a common allergic reaction or similar reaction when administered to humans, and the salt is formed by a pharmaceutically acceptable free acid. Acid addition salts are preferred. As the free acid, an organic acid and an inorganic acid can be used.
- the organic acid is not limited thereto, citric acid, acetic acid, lactic acid, tartaric acid, maleic acid, fumaric acid, formic acid, propionic acid, oxalic acid, trifluoroacetic acid, benzoic acid, gluconic acid, metasulfonic acid, glycolic acid, succinic acid, 4-toluenesulfonic acid, Glutanoic acid and aspartic acid.
- the inorganic acids include, but are not limited to, hydrochloric acid, bromic acid, sulfuric acid and phosphoric acid.
- composition of the present invention may be variously formulated according to the route of administration by a method known in the art together with a pharmaceutically acceptable carrier.
- Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations include at least one excipient in the mace lignan, for example, starch, calcium carbonate, sucrose or lactose, gelatin, etc. It is prepared by mixing. In addition, lubricants such as magnesium styrene talc are used in addition to simple excipients.
- Liquid preparations for oral administration include suspensions, intravenous solutions, emulsions, syrups, etc.
- Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, ointments and creams.
- non-aqueous solvents and suspension solvents propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used.
- composition of the present invention can be administered parenterally, parenteral administration is by subcutaneous injection, intravenous injection, intramuscular injection or intrathoracic injection injection method and transdermal administration method.
- parenteral administration is by subcutaneous injection, intravenous injection, intramuscular injection or intrathoracic injection injection method and transdermal administration method.
- mayslignan is mixed in water with a stabilizer or a buffer to prepare a solution or suspension, which is formulated into unit dosage forms of ampoules or vials.
- the dosage unit can contain, for example, 1, 2, 3 or 4 times the individual dosage, or 1/2, 1/3 or 1/4 times.
- the individual dosage preferably contains the amount of effective drug administered at one time, which usually corresponds to all, 1/2, 1/3 or 1/4 times the daily dosage.
- transdermal administration means that the pharmaceutical composition is topically administered to the skin to deliver an effective amount of the active ingredient contained in the pharmaceutical composition into the skin.
- the term 'pharmaceutically effective amount' in the present invention means an amount sufficient to alleviate skin irritation or protect the skin at a reasonable benefit / risk ratio applicable to medical uses, and the effective dose level is the individual type and severity, age, It can be determined by gender, drug activity, sensitivity to the drug, time of administration, route of administration and rate of excretion, duration of treatment, factors including co-drugs, and other factors well known in the medical field.
- the composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents. And it can be administered single or multiple. Considering all of the above factors, it is important to administer an amount that can achieve the maximum effect in a minimal amount without side effects, and can be easily determined by those skilled in the art.
- composition of the present invention may be administered in parallel with a known compound having an effect of preventing and treating skin irritation such as asthma and atopic dermatitis.
- compositions of the present invention in another aspect, there is provided a method of alleviating or inhibiting skin irritation by administering the composition of the present invention to cells, tissues, organs, or individuals exhibiting skin irritation by heavy metal or the like.
- the causative disease and pathology of skin irritation can be prevented or treated using the compositions and methods.
- the term 'individual' in the present invention means all animals, including humans, who need to alleviate skin irritation or protect the skin, and includes diseased or sensitive skin carriers of diseases accompanied by skin irritation.
- skin irritation can be alleviated or suppressed, and the skin can be protected.
- composition for alleviating skin irritation and protecting the skin of the present invention is a food composition, it can be used for skin irritation alleviation and skin protection derived from environmental pollution factors.
- the food composition of the present invention includes all forms of functional foods, nutritional supplements, health foods, food additives, and feeds, and includes animals including humans or livestock. Subject to eating. Food compositions of this type can be prepared in various forms according to conventional methods known in the art.
- the mace lignan or nutmeg extract of the present invention or a salt thereof may be prepared in the form of tea, juice, and drink for drinking or granulated, encapsulated, and powdered.
- it may be prepared in the form of a composition by mixing together with the mays lignan or nutmeg extract of the present invention and a known substance or active ingredient known to have an improvement effect on skin irritation.
- Food compositions of this type can be prepared in various forms according to conventional methods known in the art.
- Drinks including alcoholic beverages
- fruits and processed foods e.g. canned fruits, canned foods, jams, marmalades, etc.
- fish e.g. ham, sausages
- breads and noodles e.g. udon, buckwheat noodles, ramen, spagate, macaroni, etc.
- juice various drinks, cookies, syrup, dairy products (e.g.
- a nutritional supplement in addition, but not limited to, it can be prepared by adding nutmeg extract or mace lignan to capsules, tablets, pills, and the like.
- the health functional food is not limited to this, for example, nutmeg extract or mace lignan itself is prepared in the form of tea, juice and drink to be liquefied, granulated, encapsulated and powdered for drinking (health drink). Can be consumed.
- nutmeg extract or mace lignan in the form of food additives, it can be prepared and used in powder or concentrate form.
- it can be prepared in the form of a composition by mixing with nutmeg extract or known active ingredients known to have a skin irritation and skin protection effect with mace lignan.
- the health drink composition may contain various flavoring agents or natural carbohydrates, etc., as additional ingredients, as in a conventional beverage.
- the natural carbohydrates described above include monosaccharides such as glucose and fructose; Disaccharides such as maltose and sucrose; Polysaccharides such as dextrin and cyclodextrin; Sugar alcohols such as xylitol, sorbitol, and erythritol.
- Sweeteners include natural sweeteners such as taumatin and stevia extract; Synthetic sweeteners such as saccharin and aspartame.
- the proportion of the natural carbohydrate is generally about 0.01 to 0.04 g per 100 mL of the composition of the present invention, preferably about 0.02 to 0.03 g.
- Nutmeg extract or mace lignan may be contained as an active ingredient in a food composition for skin irritation relief and skin protection, the amount of which is not particularly limited to an amount effective to achieve skin irritation relief and skin protection, but is not limited to the total weight of the total composition. It may be 0.01 to 100% by weight, preferably 0.01 to 50% by weight.
- the food composition of the present invention can be prepared by mixing with nutmeg extract or macy lignan together with other active ingredients known to be effective in skin irritation and skin protection.
- the health food of the present invention includes various nutrients, vitamins, electrolytes, flavoring agents, colorants, pectic acids, salts of pectic acids, alginic acids, salts of alginic acids, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, Glycerin, alcohol or carbonic acid.
- the health food of the present invention may contain flesh for the manufacture of natural fruit juice, fruit juice beverage, or vegetable beverage. These ingredients may be used independently or in combination. The proportion of these additives is not critical, but is generally selected from 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.
- composition for alleviating skin irritation and protecting the skin of the present invention may be a cosmetic composition.
- the cosmetic composition of the present invention can be easily prepared according to methods known in the art, including one or more excipients and additives commonly used in the field of manufacturing cosmetic compositions with the mace lignan or nutmeg extract of the present invention or salts thereof. You can.
- the cosmetic composition of the present invention contains a nutmeg extract or mace lignan as an active ingredient and a basic cosmetic composition (face wash, cream, essence, cleansing foam and cleansing water-like cleansers, packs, and vodioyl), along with dermatologically acceptable excipients, It can be prepared in the form of color cosmetic composition (foundation, lipstick, mascara, makeup base), hair product composition (shampoo, conditioner, hair conditioner, hair gel) and soap.
- the excipients include, but are not limited to, for example, skin emollients, skin penetration enhancers, colorants, fragrances, emulsifiers, thickeners and solvents.
- it may further include fragrances, pigments, fungicides, antioxidants, preservatives and moisturizers, and may include thickeners, inorganic salts, synthetic polymer materials, etc. for the purpose of improving physical properties.
- the excipients include, but are not limited to, for example, skin emollients, skin penetration enhancers, colorants, fragrances, emulsifiers, thickeners and solvents.
- it may further include fragrances, pigments, fungicides, antioxidants, preservatives and moisturizers, and may include thickeners, inorganic salts, synthetic polymer materials, etc. for the purpose of improving physical properties.
- a cleanser and soap with the cosmetic composition of the present invention it can be easily prepared by adding a nutmeg extract or mace lignan to a conventional cleanser and soap base.
- the cream in the case of manufacturing the cream, it can be prepared by adding a nutmeg extract or mace lignan or a salt thereof to a cream base of a general oil-in-water type (O / W).
- Synthetic or natural materials such as proteins, minerals, vitamins, etc. for the purpose of improving physical properties may be additionally added to fragrances, chelating agents, pigments, antioxidants, preservatives, and the like.
- the face wash and soap containing the mace lignan or nutmeg extract of the present invention can be easily prepared by adding the mace lignan or nutmeg extract to the conventional face wash and soap base.
- the cream it may be prepared by adding mace lignan or nutmeg extract to a cream base of a general oil-in-water type (O / W).
- Synthetic or natural materials such as proteins, minerals, vitamins, etc. for the purpose of improving physical properties may be additionally added to fragrances, chelating agents, pigments, antioxidants, preservatives, and the like.
- the content of nutmeg extract or mayslignan contained in the cosmetic composition of the present invention is not limited thereto, but is preferably 0.001 to 10% by weight, more preferably 0.01 to 5% by weight relative to the total weight of the total composition. If the content is less than 0.001% by weight, the desired anti-aging or anti-wrinkle effect cannot be expected, and when it is more than 10% by weight, there may be difficulties in safety or preparation of the formulation.
- the present invention provides a composition for preventing skin contamination derived from environmental pollutants containing nutmeg extract or mace lignan as an active ingredient.
- composition may be provided in the form of a pharmaceutical composition, cosmetic composition, and food composition. Description of this is as described above.
- the present invention provides a use of mace lignan or a nutmeg extract containing the same for preparing a preparation for skin irritation relief and skin protection derived from environmental pollution factors.
- the present invention provides a method for alleviating skin irritation and protecting skin induced from environmental pollutants, characterized by administering an effective amount of a composition containing mace lignan or nutmeg extract containing it as an active ingredient to an individual in need thereof. do.
- the present invention provides the use of mace lignan or nutmeg extract containing the same for preparing a formulation for preventing skin contamination derived from environmental pollution factors.
- the present invention provides a method for preventing skin contamination derived from environmental pollutants, characterized by administering an effective amount of a composition containing mace lignan or nutmeg extract containing it as an active ingredient to an individual in need thereof.
- the 'effective amount' of the present invention when administered to an individual, improves, treats, prevents, detects, diagnoses skin irritation and skin damage or skin contamination, or suppresses or reduces skin irritation and skin damage or skin contamination.
- the 'individual' may be an animal, preferably a mammal, particularly an animal including a human, or may be cells, tissues, organs, etc. derived from an animal. The subject may be a patient in need of the effect.
- the 'treatment' of the present invention broadly refers to improving the symptoms of skin irritation and skin damage or skin contamination or skin irritation and skin damage or skin contamination, which heals, substantially prevents, or prevents these diseases May include, but is not limited to, alleviating, healing or preventing one symptom or most symptoms resulting from skin irritation and skin damage or skin contamination.
- the term 'comprising' of the present invention is used in the same way as 'containing' or 'as a feature', and does not exclude additional component elements or method steps not mentioned in the composition or method. .
- the term 'consisting of' means excluding additional elements, steps or ingredients, which are not described separately.
- the term 'essentially consisting of' means that in the scope of a composition or method, it includes the described component elements or steps, as well as component elements or steps that do not materially affect its basic properties.
- Nutmeg extract or mace lignan according to the present invention reduces the amount of expression of genes such as CYP1A1 mediated by XRE in skin cells, and thus has excellent skin irritation and skin protection functions derived from environmental pollutants, and is a food and cosmetic composition. Can be used for
- Figure 1 shows the results of the inhibitory activity of luciferase increase mediated by XRE according to BaP treatment of nutmeg extract.
- Figure 2 shows the results of the inhibitory activity of CYP1A1 expression increase according to BaP treatment of nutmeg extract.
- Figure 3 shows the results of the inhibitory activity of increased luciferase mediated by XRE according to BaP treatment of mace lignan.
- Figure 4 shows the results of the inhibitory activity of increased expression of CYP1A1 according to BaP treatment of mace lignan.
- Figure 5 shows the results of the inhibitory activity of increased luciferase mediated by XRE by f treatment of macylignan.
- Figure 7 shows the results of the inhibitory activity of increased expression of CYP1A1, CYP1B1, CYP1A2 mRNA by PM treatment of mays lignan.
- Figure 8 shows the results of the effect of improving skin epidermal layer damage by PM treatment of mace lignan.
- a nutmeg ethanol extract was obtained in the same manner as in Example 1-1, except that it was extracted at 50 ° C using 100% ethanol, 70% ethanol, 50% ethanol, and 30% ethanol.
- a nutmeg ethyl acetate extract was obtained in the same manner as in Example 1-1, except that 100% ethyl acetate was used.
- a nutmeg hexane extract was obtained in the same manner as in Example 1-1, except that 100% hexane was used.
- a nutmeg hot water extract was obtained in the same manner as in Example 1-2, except that water was used and the condition was 80 ° C.
- the dried nutmeg was ground with a mixer, and then 1 g of the ground nutmeg sample was charged into a sample cartridge and extracted using a supercritical device (SFX 3560, Isco Inc., Lincoln, NE, USA).
- the supercritical fluid extraction conditions were an extraction pressure of 40 MPa, an extraction temperature of 50, a supercritical carbon dioxide flow rate of 60 mL / min, and an extraction time of 60 min.
- the pressure of the extraction device was lowered to release the supercritical fluid state, thereby obtaining a nutmeg supercritical extract.
- a subcritical water reactor of a subcritical extraction device Biovan, Gyeonggi, Korea
- the temperature of the reactor was increased to 200 ° C and the pressure was increased to 20 MPa, and when the temperature of the reactor reached 200 ° C, the temperature was maintained for 20 minutes to extract.
- the extract was transferred to a storage tank to which cooling water is supplied, rapidly cooled to 30 ° C, and centrifuged at 3,600 rpm for 30 minutes to separate the floating residue, and only the supernatant was taken.
- a subcritical extract of nutmeg was prepared by removing all water using a freeze dryer (ilShin Lab Co. Ltd., Seoul, Korea).
- Example 1-2 the concentrated nutmeg ethanol extract obtained using 100% ethanol was partitioned into ethyl acetate, butanol, and water.
- the ethyl acetate fraction (4.2 g) was eluted with a solvent mixed with hexane and ethyl acetate at a ratio of 10: 1 (v / v) using silica gel column chromatography to obtain fraction III (1 g).
- Fraction III was subjected to column chromatography with a solvent mixed with hexane and ethyl acetate at a ratio of 20: 1 (v / v) to obtain fraction III-B (0.52 g).
- fraction III-B was eluted with 80% methanol using Rp-18 column chromatography (Lichroprep RP-18 25-40 um; Merck & Co.) to obtain single substance fraction III-B-2 (0.5 g).
- 1 H-NMR spectrum and 13 C-NMR spectrum were measured at 600 MHz and 150 MHz (solvent: DMSO), respectively, in order to determine the structure of the isolated single substance III-B-2.
- 13 C-NMR spectrum and the 1 H-NMR 1 H- 1 H COSY spectrum and 1 H- 13 to measure the correlation of the correlation of the 1 H- 1 H, based on the result of the spectrum related to the 1 H- 13 C HMBC C Spectra were measured.
- EI / MS for mass spectrometry of the isolated single substance [M] + was observed at m / z 328 in EI / MS and the molecular weight was found to be 328, and the molecular formula was C 20 H 24 It was O 4 .
- Example 3 XP-mediated luciferase increase inhibitory activity according to BaP treatment of nutmeg extract
- COS-7 monkey kidney cells (ATCC, Manassas, VA, USA) were cultured in Dulbecco's modified Eagle's media (DMEM; Hyclone) containing 10% fetal bovine serum (FBS; Hyclone, Logan, UT, USA) 24- Incubated in well plates for 24 hours or more.
- DMEM Dulbecco's modified Eagle's media
- FBS fetal bovine serum
- Example 4 Inhibitory activity of CYP1A1 expression increase according to BaP treatment of nutmeg extract
- the skin keratinocytes HaCaT was placed in a 6-well plate with DMEM (Hyclone) containing 10% FBS (Hyclone) to 2 x 10 5 cells / mL.
- DMEM Hyclone
- FBS Hyclone
- the nutmeg 100% ethanol extract of Example 1-2 was treated with 0.5 and 1 ⁇ g / mL for 24 hours with 5 ⁇ M BaP (Sigma-aldrich).
- total RNA was isolated using a TRIzol reagent (Takara, Tokyo, Japan). Total RNA isolated was quantified using a nanodrop (NanoDrop 1000; Thermo Fisher Scientific Inc., MA, USA).
- RNA was synthesized by cDNA under conditions of 42 ° C 55 minutes and 70 ° C 15 minutes using Reverse Transcriptase Premix (Elpis) and PCR machine (Gene Amp PCR System 2700; Applied Biosystems, MA, USA).
- Elpis Reverse Transcriptase Premix
- PCR machine Gene Amp PCR System 2700; Applied Biosystems, MA, USA.
- 3 ⁇ L cDNA the following specific primers (Bioneer, Daejeon, Korea) and PCR premix (Elpis) at 95 ° C for 30 seconds, 60 ° C for 1 minute, and 72 ° C for 1 minute 30 times PCR was performed repeatedly.
- the cDNA amplified by PCR was separated by electrophoresis with a 1.5% agarose gel, and the cDNA band was confirmed using a G; BOX EF imaging system (Syngene). The results are shown in FIG. 2.
- Reverse primer 5'-CGCCCCTTGGGGATGTAAAA-3 '(SEQ ID NO: 2)
- Reverse primer 5'-TCGCCCCACTTGATTTTGGA-3 '(SEQ ID NO: 4)
- Example 5 XRE-mediated luciferase increase inhibitory activity according to PM treatment of nutmeg extract
- Example 1-5 Nutmeg extract 50% ethanol extract and 100% ethanol extract prepared in Example 1-2, nutmeg ethyl acetate prepared in Example 1-3 to examine the luciferase inhibitory activity mediated by XRE induced by PM of nutmeg extract Extract, nutmeg hexane extract prepared in Example 1-4, Nutmeg hot water extract prepared in Example 1-5 was treated with cells at 1 ⁇ g / mL, and inducers were standardized fine dust (PM; NIST, Gaithersburg instead of BaP). , MD, USA) The experiment was carried out in the same manner as in Example 3, except that 100 ⁇ g / mL was used.
- Example 6 Inhibitory activity of CYP1A1 expression increase according to BaP treatment of maylignan
- Example 4 In order to investigate the inhibitory activity of CYP1A1 mRNA expression level of mays lignan, the cells were treated with 1 and 5 ⁇ M of mays lignan prepared in Example 2-1 to conduct experiments in the same manner as in Example 4.
- Example 7 Inhibitory activity of increased luciferase mediated by XRE by PM treatment of mays lignan
- Example 2-1 To examine the luciferase inhibitory activity mediated by XRE induced by PM of mays lignan, the mace lignan prepared in Example 2-1) was treated with cells at 0.5 and 1 ⁇ M to induce the inducer PM 100 ⁇ g / mL. The experiment was conducted in the same manner as in Example 3, except that it was used.
- Example 8 Inhibitory activity of increased expression of AhR mRNA by PM treatment of mace lignan
- the cells were treated with 0.5 and 1 ⁇ M of mays lignan prepared in Example 2-1 to use 100 ⁇ g / mL of PM.
- the experiment was conducted in the same manner as in Example 4, except that the point and the AhR primer were used.
- Reverse primer 5'-AAGCAGGCGTGCATTAGACT-3 '(SEQ ID NO: 6)
- the mays lignan of the present invention effectively reduces skin irritation caused by environmental pollutants by reducing the mRNA expression level of receptors to which environmental pollutants can bind.
- Example 9 Inhibitory activity of increased expression of CYP1A1, CYP1B1, CYP1A2 mRNA by PM treatment of mace lignan
- Example 2-1 To investigate the activity of CYP1A1, CYP1B1, and CYP1A2 mRNA expression induced by PM of mays lignan, the mace lignan prepared in Example 2-1 was treated with cells at 0.5 and 1 ⁇ M to induce the inducer PM 100 ⁇ g / mL Experiments were conducted in the same manner as in Example 4, except that and CYP1B1 and CYP1A2 primers were additionally used.
- Reverse primer 5'-AAGGAACTGGGACCTTTGCC-3 '(SEQ ID NO: 8)
- Reverse primer 5'-TGAGTGTTCTTCACGAGGCTG-3 '(SEQ ID NO: 10)
- Example 10 Effect of improving skin epidermal layer damage by PM treatment of mace lignan
- Neoderm-ED 3D artificial skin model
- the experimental group was divided into normal group, PM 100 ⁇ g / mL treatment group, mace lignan 0.5 ⁇ M treatment group, and mace lignan 1 ⁇ M treatment group, and 6 artificial skin tissues were used for each group.
- Neoderm-ED was prepared according to the method of manufacturing the tegoscience, and the experiment was conducted after stabilizing artificial skin tissue at 5% CO 2 and 37 ° C. conditions using a dedicated medium provided by tegoscience for 6 hours.
- Skin damage caused by PM was induced by treating PM 100 ⁇ g / mL with 50 ⁇ L per well on the Neoderm-ED surface, and DPBS was treated with the same dose in the normal group. Simultaneously with PM induction, the mace lignan prepared in Example 2-1 was treated with Neoderm-ED's exclusive medium at 0.5 and 1 ⁇ M to induce improvement of skin damage due to PM. The cells were cultured for 72 hours at 5% CO 2 and 37 ° C., and PM and mace lignan were further treated every 24 hours. After the 72-hour incubation, the artificial skin tissue was fixed with 10% formalin to produce a paraffin block.
- Hematoxylin & eosin staining was performed to measure the improvement of skin damage caused by PM of mace lignan from the histological aspect using the fixed tissue, and the stained tissue was eXcope T500 camera (DIXI Science, Daejeon) , Korea) was observed with a photochemical microscope (CK40; Olympus, Tokyo, Japan).
- a powder was prepared by filling in an airtight bag according to a conventional powder manufacturing method.
- tablets After mixing the nutmeg extract of Example 1 to 2, or 50 mg of maylignan, 400 mg of crystalline cellulose, and 5 mg of magnesium stearate, tablets were prepared by tableting according to a conventional tablet manufacturing method.
- Example 1 After mixing the nutmeg extract of Example 1 to 2, or 30 mg of maylignan, whey protein, 100 mg of crystalline cellulose, 400 mg of magnesium stearate, and filling it into a gelatin capsule according to a conventional capsule preparation method, a capsule is prepared. Did.
- Nutmeg extract of Examples 1 to 2 or 1000 mg of maylignan, 1000 mg of citric acid, 100 g of oligosaccharides, 2 g of plum concentrate, and 1 g of taurine were added to purified water to add the above ingredients according to the general method for preparing a health drink of 900 mL. After mixing, after stirring and heating at 85 ° C. for about 1 hour, the resulting solution is filtered, obtained in a sterilized 2 L container, sealed and sterilized, then refrigerated and then used in the manufacture of a health drink composition.
- Chewing gum was prepared by a conventional method by mixing 20% by weight of gum base, 76.9% by weight of sugar, 1% by weight of fragrance, and 2% by weight of water and 0.1% by weight of nutmeg extract or mace lignan of Examples 1 to 2 above.
- Candy was prepared by a conventional method by mixing 60% by weight of sugar, 39.8% by weight of starch syrup and 0.1% by weight of fragrance and 0.1% by weight of nutmeg extract or maceignan of Examples 1 to 2 above.
- Nutmeg extract or mace lignan of Examples 1 to 2 was prepared in the nutritional lotion according to a conventional method with the ingredients and contents of Table 2 below.
- Example 1-1 (% by weight) Nutmeg extract or mace lignan 2.0 Squalane 5.0 Wax 4.0 Polysorbate 60 1.5 Sorbitan sesquioleate 1.5 Floating paraffin 0.5 Caprylic / Capric Triglyceride 5.0 glycerin 3.0 Butylene glycol 3.0 Propylene glycol 3.0 Carboxyvinyl polymer 0.1 Triethanolamine 0.2 Preservatives, pigments, flavors Proper Purified water to 100
- the nutmeg extract or mays lignan of Examples 1 to 2 was prepared with a flexible lotion according to a conventional method with the ingredients and contents of Table 3 below.
- Nutmeg extract or mays lignan of Examples 1 to 2 was prepared in the nutritional cream according to a conventional method with the components and contents of Table 4 below.
- Massage cream was prepared according to a conventional method with the ingredients and contents of the nutmeg extract or mace lignan of Examples 1 to 2 below.
- the nutmeg extract or mace lignan of Examples 1 to 2 was prepared according to a conventional method with the ingredients and contents of Table 6 below.
- the nutmeg extract or mace lignan of Examples 1 to 2 was prepared according to a conventional method with the ingredients and contents of Table 7 below.
- the present invention relates to a composition for alleviating skin irritation and protecting skin derived from environmental contaminants containing nutmeg extract or macy lignan as an active ingredient. More specifically, the nutmeg extract and mays lignan of the present invention reduced the expression of CYP1A1 gene mediated by XRE in skin cells and improved the skin damaged by fine dust, and thus skin irritation caused by fine dust, heavy metals, or yellow dust It has an excellent effect on relief and skin protection. Therefore, the nutmeg extract and mace lignan of the present invention is a natural product, and thus can be safely used without side effects, and is highly industrially applicable because it can provide a composition showing excellent effects on skin irritation and skin protection.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Birds (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201980086457.XA CN113613666A (zh) | 2018-10-26 | 2019-10-24 | 包含肉豆蔻提取物或肉豆蔻木酚素作为有效成分的用于缓解由环境污染因素引起的皮肤刺激及保护皮肤的组合物 |
JP2021523078A JP2022505979A (ja) | 2018-10-26 | 2019-10-24 | ナツメグエキス又はメイスリグナンを有効成分として含有する、環境汚染因子から誘導される皮膚刺激緩和及び皮膚保護用組成物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2018-0129382 | 2018-10-26 | ||
KR20180129382 | 2018-10-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020085826A1 true WO2020085826A1 (ko) | 2020-04-30 |
Family
ID=70331701
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2019/014101 WO2020085826A1 (ko) | 2018-10-26 | 2019-10-24 | 육두구 추출물 또는 메이스리그난을 유효성분으로 함유하는 환경오염인자로부터 유도되는 피부자극 완화 및 피부보호용 조성물 |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP2022505979A (ja) |
KR (1) | KR20200047422A (ja) |
CN (1) | CN113613666A (ja) |
WO (1) | WO2020085826A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102242195B1 (ko) * | 2020-06-16 | 2021-04-21 | 주식회사 웰니스바이오 | 비알코올성 지방간 질환의 개선, 예방 또는 치료용 조성물 및 그 제조방법 |
KR102162377B1 (ko) * | 2020-06-19 | 2020-10-06 | 주식회사 민디민메디컬그룹 | 천연물 유래 추출물 및 이를 포함하는 화장료 조성물 및 이의 제조방법 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100567431B1 (ko) * | 2004-01-08 | 2006-04-04 | 황재관 | 리그난계 화합물을 유효성분으로 함유하는 여드름 치료 또는 예방용 조성물 |
KR20110119482A (ko) * | 2010-04-27 | 2011-11-02 | (주)뉴트리 | 알레르기성 질환의 예방 및 치료용 조성물 |
KR20110119483A (ko) * | 2010-04-27 | 2011-11-02 | (주)바이오케어 | 메이스리그난 또는 육두구 추출물을 유효성분으로 하는 가려움증 완화 또는 피부손상 개선용 조성물 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100627643B1 (ko) * | 2005-06-27 | 2006-09-25 | 황재관 | 제 2 형 당뇨병 치료 또는 예방용 약제학적 조성물 |
KR101404398B1 (ko) * | 2007-06-20 | 2014-06-09 | (주)뉴트리 | 주름개선 화장료 조성물 |
CN101827579B (zh) * | 2007-10-17 | 2013-01-23 | 生物关怀有限公司 | 木酚素系化合物或含有该化合物的肉豆蔻提取物或肉豆蔻假种皮提取物的新用途 |
-
2019
- 2019-10-24 CN CN201980086457.XA patent/CN113613666A/zh active Pending
- 2019-10-24 JP JP2021523078A patent/JP2022505979A/ja active Pending
- 2019-10-24 WO PCT/KR2019/014101 patent/WO2020085826A1/ko active Application Filing
- 2019-10-25 KR KR1020190133679A patent/KR20200047422A/ko not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100567431B1 (ko) * | 2004-01-08 | 2006-04-04 | 황재관 | 리그난계 화합물을 유효성분으로 함유하는 여드름 치료 또는 예방용 조성물 |
KR20110119482A (ko) * | 2010-04-27 | 2011-11-02 | (주)뉴트리 | 알레르기성 질환의 예방 및 치료용 조성물 |
KR20110119483A (ko) * | 2010-04-27 | 2011-11-02 | (주)바이오케어 | 메이스리그난 또는 육두구 추출물을 유효성분으로 하는 가려움증 완화 또는 피부손상 개선용 조성물 |
Non-Patent Citations (2)
Title |
---|
CHUNG, HEE CHUL: "Effects of Myristica fragrans Houtt. Extract and Its Active Compound Macelignan on Atopic Dermatitis-like Skin NC/Nga Mouse Induced by Dermatophagoides farinae Crude Extract", PHD THESIS, GRADUATE PROGRAM IN BIOMATERIALS SCIENCE AND ENGINEERING, DEPARTMENT OF BIOTECHNOLOGY, THE GRADUATE SCHOOL OF YONSEI UNIVERSITY, 2012, pages 1 - 105 * |
LEE, K.-E.: "Effects of macelignan isolated from Myristica fragrans (Nutmeg) on expression of matrix metalloproteinase-1 and type I procollagen in UVB-irradiated human skin fibroblasts", BIOLOGICAL AND PHARMACEUTICAL BULLETIN, 16 October 2012 (2012-10-16), pages 69 - 1675 * |
Also Published As
Publication number | Publication date |
---|---|
KR20200047422A (ko) | 2020-05-07 |
JP2022505979A (ja) | 2022-01-14 |
CN113613666A (zh) | 2021-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018124508A1 (ko) | 3,5-디카페오일퀴닉에시드 또는 국화 추출물을 함유하는 근육 질환 예방 및 치료용 또는 근 기능 개선용 조성물 | |
WO2020218720A1 (ko) | 익모초 추출물 또는 레오누린을 함유하는 근육 질환 예방 또는 치료용 또는 근 기능 개선용 조성물 | |
WO2020085826A1 (ko) | 육두구 추출물 또는 메이스리그난을 유효성분으로 함유하는 환경오염인자로부터 유도되는 피부자극 완화 및 피부보호용 조성물 | |
WO2015037778A1 (ko) | 리그난 화합물을 유효 성분으로 포함하는 암의 예방 또는 치료용 조성물 | |
WO2018070707A1 (ko) | 데칸알 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 근육 질환 예방 또는 치료용 조성물 | |
WO2014003232A1 (ko) | 황칠나무 추출물을 유효성분으로 포함하는 발모 촉진용 조성물 | |
WO2018062820A1 (ko) | 피토에스트로겐을 유효성분으로 포함하는 탈모방지 및 모발 성장 촉진용 조성물 | |
WO2018070705A1 (ko) | 디오스민 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 근육 질환 예방 또는 치료용 조성물 | |
WO2018236186A1 (ko) | 세스퀴테르펜 유도체를 유효성분으로 함유하는 근육 질환 예방 또는 치료용 조성물 | |
WO2018186641A1 (ko) | 피페로날 또는 이의 염을 유효성분으로 함유하는 피부주름 개선, 보습, 탄력증진, 각질제거, 홍반억제 또는 피부광노화 개선용 조성물 | |
WO2020032435A1 (ko) | 야라야라를 유효성분으로 포함하는 탈모 방지 또는 발모 촉진용 조성물 | |
WO2010041908A2 (ko) | 판두라틴 유도체 또는 보에센베르기아 판두라타 추출물의 신규한 용도 | |
WO2016190689A2 (ko) | 근육 질환 예방, 개선 또는 치료용 또는 근 기능 개선용 조성물 | |
WO2020145619A1 (ko) | 운데칸 또는 운데칸알을 유효성분으로 포함하는 항알러지, 아토피 피부염 개선, 또는 피부 재생용 조성물 | |
WO2015037855A1 (en) | A composition comprising an extract of combined herbs consisting of acanthopanax koreanum nakai and crinum asiaticum var. japonicum showing preventing activity of baldness and stimulating activity of hair growth | |
WO2019017677A9 (ko) | 시트랄을 유효성분으로 함유하는 근력강화, 근육증강, 근육분화, 근육재생 또는 근감소증 억제효과를 갖는 조성물 | |
WO2020130478A1 (ko) | 자스몬을 유효성분으로 포함하는 항알러지, 아토피 피부염 개선, 또는 피부 재생용 조성물 | |
WO2009151236A2 (en) | The composition comprising extracts or fractions of magnolia obovata thunb for treating and preventing inflammation disease | |
WO2019027239A2 (ko) | 탈모 방지 또는 발모 촉진용 조성물 | |
WO2019172566A1 (ko) | 이오논을 유효성분으로 함유하는 항스트레스제, 항우울제 또는 항불안제 조성물 | |
WO2021167120A1 (ko) | 구아일아세테이트를 유효성분으로 포함하는 항알러지, 아토피 피부염 개선, 또는 피부 재생용 조성물 | |
WO2021034080A1 (ko) | 카르본 또는 이의 염을 유효성분으로 포함하는 알러지성 질환 또는 아토피 피부염 예방 또는 치료용 조성물 | |
WO2021034082A1 (ko) | 오시멘, 캠퍼 또는 이의 염을 유효성분으로 포함하는 알러지성 질환 또는 아토피 피부염 예방 또는 치료용 조성물 | |
WO2019083287A2 (ko) | 펠란드렌을 유효성분으로 포함하는 탈모 방지 또는 발모 촉진용 조성물 | |
WO2021167121A1 (ko) | 노네인을 유효성분으로 포함하는 항알러지, 아토피 피부염 개선, 또는 피부 재생용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19877326 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021523078 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19877326 Country of ref document: EP Kind code of ref document: A1 |